

Curriculum Vitae

**CV must be written in English*

Personal Information

	Title (i.e. Prof., Dr., etc.)	Prof.
	Name (First / Middle / Last)	Shu-Chen Wei
	Degree (i.e. MD, MSc, PhD, etc.)	MD, PhD, AGAF
	Country	Taiwan
	Affiliation	National Taiwan University Hospital

Educational Background

- 1985.09-1992.06 M.D., College of Medicine, Chung - Shan Medical University, Taiwan
1997.09-2004.01 PhD, Graduate Institute of Clinical Medicine, National Taiwan University, Taiwan
2006.07-2008.06 Post-Doc (Research fellow), GI Unit & CSIBD (Center for study of IBD), MGH, Boston, USA

Professional Experience

- 2025.11 – present President of TSIBD (Taiwan Society of inflammatory bowel disease)
2025 -- present Educational Committee member of AOCC
2024- present Advisory board member of AOCC Governing Board
2020- present American Gastroenterology Association Fellow
2025- present Honorary Fellow of the Hong Kong Society of Gastroenterology
2026- 2028 Global Task Force Member (elected by ECCO committee)

Professional Organizations

- The Society of Internal Medicine, Taiwan
The Society of Gastroenterology, Taiwan
The Society of Gastrointestinal Endoscopy, Taiwan
Taiwan Society of Inflammatory Bowel Disease (TSIBD)
International Member of American Gastroenterology Association (AGA)
European Organization of Crohn's and Colitis (ECCO)
Asian Organization for Crohn's and Colitis (AOCC)

Main Scientific Publications

- Weng MT, Yao CY, Lin WC, Lai SK, Tung CC, Wang CY, Wong JM, Chen PL, **Wei SC***. HLA-C*03:04:01 and HLA-B*15:18:01 but not HLA-DQA1*05 associated with anti-TNF antibody formation in Taiwanese inflammatory bowel disease patients. *World J Gastroenterol.* 2025 Nov 7;31(41):111745.
- Wu HY, Yang CY, Weng MT, Tung CC, Wong JM, **Wei SC***. Demodicosis Mimics Acneiform Eruptions in Patients with Inflammatory Bowel Disease Receiving Upadacitinib: A Case Series. *Am J Gastroenterol.* 2025 Oct 22. doi: 10.14309/ajg.0000000000003813. Online ahead of print.
- Tsai FP, Weng MT, Wu HY, Chen ZC, Tung CC, Wang CY, **Wei SC***. Fecal leukocyte esterase levels predict endoscopic severity as an alternative biomarker in inflammatory bowel disease. *Clin Chem Lab Med.* 2025 Sep 1. doi: 10.1515/cclm-2025-0747. Online ahead of print.

4. Mahadevan U, Seow CH, Barnes EL, Chaparro M, Flanagan E, Friedman S, Julsgaard M, Kane S, Ng S, Torres J, Watermeyer G, Yamamoto-Furusho J, Robinson C, Fisher S, Anderson P, Geary R, Duricova D, Dubinsky M, Long M; Global Consensus Group for Pregnancy in IBD. Global consensus statement on the management of pregnancy in inflammatory bowel disease. *Gut*. Aug 28;gutjnl-2025-336402. doi: 10.1136/gutjnl-2025-336402.
5. Hracs L, Windsor JW, Gorospe J, Cummings M, Coward S, Buie MJ, Quan J, Goddard Q, Caplan L, Markovinović A, Williamson T, Abbey Y, Abdullah M, Abreu MT, Ahuja V, Raja Ali RA, Altuwaijri M, Balderramo D, Banerjee R, Benchimol EI, Bernstein CN, Brunet-Mas E, Burisch J, Chong VH, Dotan I, Dutta U, El Ouali S, Forbes A, Forss A, Geary R, Dao VH, Hartono JL, Hilmi I, Hodges P, Jones GR, Juliao-Baños F, Kaibullayeva J, Kelly P, Kobayashi T, Kotze PG, Lakatos PL, Lees CW, Limsrivilai J, Lo B, Loftus EV Jr, Ludvigsson JF, Mak JWY, Miao Y, Ng KK, Okabayashi S, Olén O, Panaccione R, Paudel MS, Qureshi AB, Rubin DT, Simadibrata M, Sun Y, Suzuki H, Toro M, Turner D, Iade B, **Weir SC**, Yamamoto-Furusho JK, Yang SK, Ng SC, Kaplan GG; Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES -21) Research Group. Global evolution of inflammatory bowel disease across epidemiologic stages. *Nature*. 2025 Apr 30. doi: 10.1038/s41586-025-08940-0. Online ahead of print.
6. Chen CN, Wu HY, Weng MT, Huang CB, Tung CC, **Weir SC***, Tsao PN*. Pregnancy and Perinatal Outcomes of Mothers with Inflammatory Bowel Disease in Taiwan: A National Database Analysis. *J Formos Med Assoc*. 2025 Mar 5;S0929-6646(25)00100-7.
7. Hsueh WY, Wu YL, Weng MT, Liu SY, Santavanond JP, Liu YC, Lin CI, Lai CN, Lu YR, Hsu JY, Gao HY, Lee JC, **Weir SC**, Lyu PC, Poon IKH, Hsing-Pang Hsieh HP, Chiu YH. Novel naphthylidones targeting Pannexin 1 for colitis management. *Adv Sci (Weinh)*. 2025 Feb;12(7):e2411538.
8. Wu HY, Weng MT, Chou JW, Yen HH, Lin CC, Chiang FF, Chung CS, Lin WC, Chang CW, Le PH, Kuo CJ, Lin CP, Hsu WH, Chuang CH, Tsai TJ, Feng IC, **Weir SC*** (co-correspondence), Huang TY. Clinical Characteristics, Management and Outcomes of Colitis-associated Colorectal Cancer and the Comparison to Sporadic Colorectal Cancer in Taiwan. *Clin Transl Gastroenterol*. 2025 Feb 1;16(2):e00798.
9. Huang CW, **Weir SC**, Shieh MJ, Chou JW, Chuang CH, Wang HY, Chang CW, Wu DC, Huang TY, Liu YH, Tsai TJ, Tai WC, Tai CM, Chung CS, Tsai WS, Chang CH, Lin CP, Lee HC, Chang CC, Feng IC, Lin CC, Cheng ML, Yen HH. Epidemiology and temporal trends of adult inflammatory bowel disease in Taiwan: Multicenter study from the TSIBD registration. *J Formos Med Assoc*. 2025 Jan 31;S0929-6646(25)00034-8.
10. Lin WC, Lin CC, Hsu WH, Chiang FF, Chang CW, Hsu TC, Wu DC, Wang HY, Wong JM, **Weir SC***. Short-term and long-term outcomes of acute severe ulcerative colitis in Taiwan: a multicenter study with pre- and post-biologics comparison. *Intest Res*. 2025 Jan 24. doi: 10.5217/ir.2024.00112. Online ahead of print.
11. Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanna J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. *Lancet*. 2025 Jan 4;405(10472):33-49.
12. Zheng J, Sun Q, Zhang M, Liu C, Su Q, Zhang L, Xu Z, Lu W, Ching J, Tang W, Cheung CP, Hamilton AL, Wilson O'Brien AL, **Weir SC**, Bernstein CN, Rubin DT, Chang EB, Morrison M, Kamm MA, Chan FKL, Zhang J, Ng SC. Noninvasive, microbiome-based diagnosis of inflammatory bowel disease. *Nat Med*. 2024 Dec;30(12):3555-3567.